Literature DB >> 15589038

Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination.

Wen-Wu Li1, Anna Setzu, Chao Zhao, Robin J M Franklin.   

Abstract

Minocycline, a tetracycline derivative, disrupts inflammatory processes within the CNS and reduces demyelination in experimental autoimmune encephalomyelitis. Several recent studies indicate that components of the inflammatory response to demyelination may be beneficial for the regenerative process of remyelination. In this study we examined the effects of minocycline on remyelination independent of its effects in limiting immune-mediated white matter damage using a toxin model of demyelination. Demyelinating lesions were induced by injection of ethidium bromide into caudal cerebellar peduncles of adult rats. Minocycline or PBS was administered by twice daily injections from day 1 prior to lesion-induction to post lesion day 3. Remyelination was assessed, blinded to grouping, using standard morphological criteria. The microglia activation within the lesion was assessed by examining the expression of OX-42 and major histocompatibility class II immunoreactivity. The oligodendrocyte progenitor cell (OPC) response was quantified by in situ hybridization using probes for OPC-expressed mRNAs, platelet-derived growth factor receptor-alpha and Olig-1. Minocycline treatment strongly inhibited microglia/macrophage activation at day 1 and day 3 post-lesion induction, and suppressed the OPC response to demyelination. We also found a significant decrease in the extent of oligodendrocyte but not Schwann cell remyelination in the minocycline-treated animals as compared with controls at 3 weeks post-lesion induction. These results indicate that microglia/macrophage activation is an important process for remyelination and further support the concept that suppression of inflammatory response may impair remyelination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15589038     DOI: 10.1016/j.jneuroim.2004.08.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  57 in total

1.  Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury.

Authors:  Jee Y Lee; So R Kang; Tae Y Yune
Journal:  J Neurotrauma       Date:  2015-03-06       Impact factor: 5.269

Review 2.  The effect of morphine on glial cells as a potential therapeutic target for pharmacological development of analgesic drugs.

Authors:  Haroon Hameed; Mariam Hameed; Paul J Christo
Journal:  Curr Pain Headache Rep       Date:  2010-04

Review 3.  Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Authors:  Martin Stangel; Corinna Trebst
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

4.  Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis.

Authors:  Oleg Butovsky; Gennady Landa; Gilad Kunis; Yaniv Ziv; Hila Avidan; Nadav Greenberg; Adi Schwartz; Igor Smirnov; Ayala Pollack; Steffen Jung; Michal Schwartz
Journal:  J Clin Invest       Date:  2006-03-23       Impact factor: 14.808

Review 5.  Neuroprotection and neuroregeneration in multiple sclerosis.

Authors:  Martin Stangel
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 6.  Oligodendrocyte-microglia cross-talk in the central nervous system.

Authors:  Laura Peferoen; Markus Kipp; Paul van der Valk; Johannes M van Noort; Sandra Amor
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

Review 7.  The origin, fate, and contribution of macrophages to spinal cord injury pathology.

Authors:  Lindsay M Milich; Christine B Ryan; Jae K Lee
Journal:  Acta Neuropathol       Date:  2019-03-30       Impact factor: 17.088

8.  Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair.

Authors:  Juan Carlos Biancotti; Shalini Kumar; Jean de Vellis
Journal:  Neurochem Res       Date:  2008-07-26       Impact factor: 3.996

Review 9.  Progress in periventricular leukomalacia.

Authors:  Wenbin Deng; Jeanette Pleasure; David Pleasure
Journal:  Arch Neurol       Date:  2008-10

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.